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Recent studies indicated that the formation of a major constituent of Alzheimer’s disease (AD) senile plaques, called BACpeptide, does not result 
from normal processing of its precursor, amyloid precursor protein (APP). Since protcolytic cleavage of APP inside its /?A4 sequence was found 
to be part of APP processing the formation of the PA4-peptide seems to be prevented under normal conditions. We considered whether in AD 
one of the endogenous proteinase inhibitors might interfere with APP proce s mg. After we had recently found that cultured human ncuronal cells s’ 
synthesize the most potent of the known human proteinase inhibitors, a-t-macroglobulin (arZM), upon stimulation with the inflammatory mediator 
interleukin-6 (IL-6) we now investigated whether or2M and IL-6 could be detected in AD brains. Here we report that AD cortical senile plaques 
display strong u2M and IL-6 immunoreactivity while no such immunoreactivity was found in age-matched control brains. Strong perinuclear KIM 
immunoreactivity in hippocampal CA1 neurons of Alzheimer’s discasc brains indicates that neuronal cells are the site of ~t2M synthesis in AD 
brains. We did not detect elevated IL-6 or or2M levels in the cerebrospinal fluid of AD patients. Our data indicate that a sequence of immunological 
events which seem to be restricted to the local cortical environment is part of AD pathology. 
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1. INTRODUCTION 
A peptide of 42-43 amino acids with a high tendency 
to aggregate, called /3A4 protein @A4), has been iden- 
tified as a major proteinaceous component of 
Alzheimer’s disease (AD) senile plaques (reviewed in 
[l-3]). /3A4 is derived from a 90-140 kDa precursor, 
called amyloid precursor protein (APP), which, due to 
differential splicing of its hn mRNA, is translated into 
three major protein forms (with 695, 751, and 770 
amino acids, respectively) [l-3]. APP is constitutively 
expressed by neuronal and non-neuronal cells in brains 
of both healthy individuals and AD patients. A recent 
study revealed that no differences in the 770:751:695 
ratio could be found between normal aged persons and 
AD patients [4]. This ratio, however, is changed along 
development and along normal aging [4]. A recently 
described single point mutation of the APP gene could 
be found only in a minority of familial AD patients (2 
out of 11 investigated cases) while a majority of familial 
and all of the investigated non-fami!ia AD cases lack 
this mutation 151. 
Studies on APP expression in cell cultures revealed 
that APP is inserted as a transmembrane protein by the 
synthesizing cells [l-3]. The PA4 sequence of APP 
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spans from the middle of the membrane to the ex- 
tracellular part of the APP molecule [l-3]. Normal pro- 
cessing of APP then includes its proteolytic cleavage in- 
side the PA4 sequence by a still unknown secretase 
resulting in the release of the large extracellular, N- 
terminal part of APP [6,7]. Thus, the formation of PA4 
is prevented by normal APP processing. We considered 
whether in AD one of the endogenous human protease 
inhibitors might inhibit the normal cleavage of APP 
and m.ay thus give rise to the breakdown product PA4 
which, due to its tendency to aggregate, could then con- 
tribute to plaque formation. After we had found that 
cultured human neuronal cells could be induced to syn- 
thesize the most potent of the known human proteinase 
inhibitors, cr-Zmacroglobulin ((r2M), upon stimulation 
with the inflammatory mediator interleukin-6 (IL-6) 
[PI, we now immunohistochemically examined AD cor- 
tices for the presence of c~2M and IL-6. 
2. MATERIALS AND METHODS 
Formalin-fixed paraffin-embedded sections of different isocortical 
(frontal, parietal and occipital) and hippocampal areas from 6 cases 
of AD confirmed by clinical and independent histopathological es- 
amination (ages 66, 69, 70, 73, 76 and 78) and brain sections of the 
same areas from normal aged-matched control persons without any 
neuropathological diagnosis were immunohistochcmically in- 
vcstigated for APP (with monoclonal anti-APP, Boehringer, Mann- 
hcim, Germany (not shown), CUZIM, and IL-6 immunoreactivity. After 
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incubation with the primary monospecific rabbit antibodies 
polyclonal anti-cu2M [9] and anti-IL-6 (Genzyme, Boston, MA), im- 
munostaining was performed with the avidin-biotin-peroxidase com- 
plex method (Vectastain, Vector Laboratories, Burlingame, CA). 
Peroxidase activity was developed with diaminobenzidine (Sigma, 
Deisenhofen, Germany) / HzOz. The sections were counterstained 
with hematoxylin. Control stains were performed separately (i) with 
non-immune rabbit control serum and showed no or only very low 
background staining and (ii) by saturating the specific antibodies with 
their purified antigens (IL-6 or o12M, respectively) prior to im- 
munohistochemistry resulting in abolisment of the immunostaining. 
3. RESULTS AND DISCUSSION 
Isosortical and hippocampal AD senile plaques, 
which as expected could consistently be stained for 
APP (not shown), displayed strong c~2M (Fig. IA) and 
IL-6 immunoreactivity (Fig. 1B). This was a consistent 
finding in all investigated AD cases. In addition, large 
neurons of the AD cortices, mainly in the hippocampal 
CA1 region, showed a pronounced intracellular, 
perinuclear cr2M stain (Fig. 2A) which was absent in 
normal aged brains. This points to a2M synthesis in 
these cells. Furthermore, the bodies of many large 
neurons, mainly in the isocortical areas, were surround- 
ed by an edge of strong IL-6 immunoreastivity (Fig. 29) 
indicating binding of IL-6 to these neurons. Since no 
antigenic cross-reactivity with other proteins has been 
reported neither for (r2M nor for IL-6, our observations 
suggest he actual presence of a2M and IL-G (or of their 
respective breakdown products) in AD senile plaques. 
Unspecific staining could be excluded by extensive con- 
trol studies (i) with several non-immune sera which 
showed no or only extremely low background staining 
Fig. 1. ImmunohistochernicaI detection of (u2M (A) and IL-6 (B) immunoreactivity in AD senile plaques (parietal section, magnification x 512). 
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(not shown) and (ii) by pre-absorbing the antibodies 
with their respective antigens prior to the im- 
munohistochemical procedure resulting in complete 
disappearance of the signals (not shown). 
We have previously found chat spontaneous &&I 
syn.thesis in cultured human neuronal cells is very low 
but can be strongly induced (more than 20-fold) upon 
stimulation. of the cells with IL-6 in a dose- and time- 
dependent manner [&I. This observation suggests that 
the detected immunoreactivities for IL-6 and a2M in 
AD brains may be functionally connected. In addition 
to neuronal cells, we previously identified astrocytes as 
a potential site of a2M synthesis [IO]. Recently, we 
found that cx2M may interfere with APP processing 181. 
However, it is still unclear whether CY%M may affect 
APP processing directly (e.g. by inhibiting the pro- 
Fig. 2. Immunohistochemical detection of intracellular, perinuclear cr2M imlnunoreactivity in AD brain large hippocampal CAL neurons (A). 
Detection of pericellular IL-G immunoreactivity around a neuronal cell in an AD brain parietal section (B). Note the additional IL-6 staining of 
a senile plaque in (B) (magnification x 600). 
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teolytic secretase) or indirectly (e.g. by affecting 
neuronal cell vitality via other unknown mechanisms). 
The peptide IL-6 is one of the endogenous inflam- 
matory mediators or cytokines, which are synthesized 
by the host upon injury or infection [11,12] (for review 
see [13,14]). Along with tumor necrosis factor CY and 
interleukin-1, IL-6 induces a complex reaction of the 
host called the acute-phase response [ 151. In the brain, 
IL-6 can be synthesized by microglia, astrocytes, and 
endothelial cells [16]. IL-6 synthesis requires previous 
stimulation of the synthesizing cells, e.g. by bacteria, 
viruses or immune complexes. When using commercial- 
ly available IL-6 ELISA’s, we did not find elevated IL-6 
levels in the cerebrospina1 fluid of IO AD patients in- 
vestigated so far. In our hands, also (r2M could not be 
detected in the unconcentrated cerebrospinal fluids of 
AD patients. Therefore expression of IL-6 and ar2M 
seems to be restricted to the intracortical environment. 
Our data make it necessary to further investigate what 
may trigger local IL-6 synthesis in AD brains. 
a-2-Macroglobulin (a2M) is the most potent of the 
known human proteinase inhibitors (reviewed in [17]). 
This protein is mainly synthesized by the liver both in 
man and in the rat. In the rat, hepatic c~2M synthesis is 
strongly indused by the cytokine IL-6 resulting in 
elevated serum levels upon injury or infection [l&21]. 
Therefore, in this species c~2M belongs to the so-called 
acute-phase proteins. In man, a2M serum levels do not 
increase during the acute-phase response why con- 
stitutive expression by the liver is assumed [17]. 
However, our recent finding that a2M synthesis can be 
strongly induced in human neuronal cells upon incuba- 
tion with IL-6 [8] provides evidence that ot2M may be- 
have as an acute-phase protein also in man, at least in 
the central nervous system. 
In the central nervous system, important events such 
as neuronal cell migration during brain development 
and neurite outgrowth after tissue damage have been 
found to depend on a precarious balance between pro- 
teases and their inhibitors (reviewed in [22]). An impor- 
tant roIe of cr2M for brain development and neuronal 
plasticity is suggested by the finding of transient cr2M 
expression in the developing brain [23,24]. Since (abor- 
tive) neurite sprouting is consistently found around AD 
senile plaques, the detection of a2M in plaques may be 
of special significance. In contrast to AD brains, we 
could hardly detect any u2M immunoreactivity in cor- 
tices of age-matched normal brains (not shown) confir- 
ming a previous report by other investigators [25]. 
In conclusion, a sequence of immunological events 
starting with IL-Ginduced cortical synthesis of a2M 
and possibly ending with altered APP processing may 
be hypothesized. At least, there is now clear evidence 
that a kind of acute-phase response is involved in AD 
pathology. 
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